Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

The highly selective BCL2 inhibitor venetoclax achieves deep responses in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL), including undetectable minimal residual disease (uMRD). We retrospectively reviewed 62 patients with CLL treated with venetoclax to investigate the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Lew, Thomas E., Anderson, Mary Ann, Lin, Victor S., Handunnetti, Sasanka M., Came, Neil A., Blombery, Piers, Westerman, David A., Wall, Meaghan, Tam, Constantine S., Roberts, Andrew W., Seymour, John F.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2020
Soggetti:
Lymphoid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6960473/
https://ncbi.nlm.nih.gov/pubmed/31935286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000864
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi